This NEJM editorial discussed the implications of finerenone for diabetic kidney disease in type 1 diabetes, evaluating whether the cardiorenal benefit extends beyond the type 2 diabetes population.
New England Journal of Medicine, Volume 394, Issue 10, Page 1019-1020, March 5, 2026.
